ReviewGenes and immunity2011
TIM polymorphisms--genetics and function.
Review in Genes and immunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- TIM3 in COVID-19; A potential hallmark?Heliyon · 2024Review
- Molecular Basis for the Differential Function of HAVCR1 Mucin Variants.Biomedicines · 2024Article
- B7-1 and PlGF-1 are two possible new biomarkers to identify fracture-associated trauma patients at higher risk of developing complications: a cohort study.BMC musculoskeletal disorders · 2024Article
- Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy.Cellular and molecular life sciences : CMLS · 2024Review
- NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.Frontiers in immunology · 2024Review
- Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients.Frontiers in immunology · 2024Review
- TIM-3 regulates the proliferation by BDNF-mediated PI3K/AKT axis in the process of endometriosis.Molecular medicine (Cambridge, Mass.) · 2023Article
- Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.Molecular cancer · 2023Review
- Function and characteristics of TIM‑4 in immune regulation and disease (Review).International journal of molecular medicine · 2023Review
- Immune checkpoint molecules in prevention and development of asthma.Frontiers in immunology · 2023Review
- Single Nucleotide Variants of the Human TIM-1 IgV Domain with Reduced Ability to Promote Viral Entry into Cells.Viruses · 2022Article
- TIM-1 promotes proliferation and metastasis, and inhibits apoptosis, in cervical cancer through the PI3K/AKT/p53 pathway.BMC cancer · 2022Article
- Tim-3 is dispensable for allergic inflammation and respiratory tolerance in experimental asthma.PloS one · 2021Article
- TIM-3 Genetic Variants Are Associated with Altered Clinical Outcome and Susceptibility to Gram-Positive Infections in Patients with Sepsis.International journal of molecular sciences · 2020Article
- Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.Seminars in cancer biology · 2020Review
- Tim-3 finds its place in the cancer immunotherapy landscape.Journal for immunotherapy of cancer · 2020Review
- Targeting novel inhibitory receptors in cancer immunotherapy.Seminars in immunology · 2020Review
- The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity.Cell research · 2020Review
- Histone Methylation Inhibitor DZNep Ameliorated the Renal Ischemia-Reperfusion InjuryFrontiers in medicine · 2020Article
- Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The transmembrane immunoglobulin and mucin domain (TIM) family was identified more than a decade ago. Although the founding member of the family was first described in a rat model of ischemia-reperfusion injury, much of the recent interest in the TIM family members has focused on their potential roles in immunity. There are now a large number of genetic studies that have investigated the possible association of various TIM1 and TIM3 polymorphisms with different diseases. Here, we review this body of literature, and highlight some of the most interesting studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.